Who is on it, and how far along Every drug ChEMBL records acting on TNF, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Antibody 9 Protein or peptide 4 Other 2 Approved5 Adalimumab Adalimumab SponsorSurmount Services, Inc. ModalityAntibody ActionInhibitor Open trials111 Infliximab Infliximab SponsorMirador Therapeutics, Inc. ModalityAntibody ActionInhibitor Open trials99 Etanercept Etanercept SponsorSorrento Therapeutics, Inc. ModalityProtein or peptide ActionInhibitor Open trials32 Golimumab Golimumab SponsorBristol-Myers Squibb ModalityAntibody ActionInhibitor Open trials21 Certolizumab pegol Certolizumab pegol SponsorUCB ModalityAntibody ActionInhibitor Open trials15 Phase 33 Lenercept Lenercept SponsorNot known ModalityProtein or peptide ActionInhibitor Open trials0 Nerelimomab Nerelimomab SponsorNot known ModalityAntibody ActionInhibitor Open trials0 Onercept Onercept SponsorMerck KGaA ModalityProtein or peptide ActionInhibitor Open trials0 Phase 27 ABBV-3373 ABBV-3373 SponsorAbbVie ModalityOther ActionBinding agent Open trials0 Afelimomab Afelimomab SponsorNot known ModalityAntibody ActionInhibitor Open trials0 AZ9773 AZ9773 SponsorNot known ModalityOther ActionInhibitor Open trials0 Ozoralizumab Ozoralizumab SponsorSanofi ModalityAntibody ActionInhibitor Open trials0 Pegsunercept Pegsunercept SponsorAmgen ModalityProtein or peptide ActionInhibitor Open trials0 Placulumab Placulumab SponsorArana Therapeutics Ltd ModalityAntibody ActionInhibitor Open trials0 Remtolumab Remtolumab SponsorAbbVie ModalityAntibody ActionInhibitor Open trials0
The landscape Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 14 of 15 act as: TNF-alpha inhibitor; the rest name their own mechanism.
Open trials The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 31 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Non-Invasive Biomarker Monitoring in UC on Biologics Infliximab — Not yet recruiting University Hospitals Coventry and Warwickshire NHS Trust Nov 5, 2026 Efficacy and Safety of Adalimumab for the Treatment of Ocular Inflammation Adalimumab Not applicable Not yet recruiting Samsung Medical Center Nov 3, 2026 Withdrawal Versus Continued TNF Inhibitor Monotherapy Treatment in Children With Inactive Juvenile Idiopathic Arthritis Adalimumab, Etanercept, Golimumab Phase 4 Not yet recruiting Oslo University Hospital Oct 29, 2026 Precision Depression Adalimumab Trial Adalimumab Phase 2 Recruiting Daniel Moriarity Sep 29, 2026 Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimekizumab Adalimumab Phase 3 Not yet recruiting University Hospital, Rouen Sep 23, 2026 Conventional vs Biologic Therapy in Pediatric IBD Adalimumab, Infliximab — Not yet recruiting Assiut University Sep 14, 2026 A Study to Investigate How Well an Intracolonic Formulation of Two Monoclonal Antibodies is Tolerated in Healthy Participants and the Ability for the Antibodies to be Taken up by the Body Via the Colon Adalimumab Phase 1 Recruiting Surmount Services, Inc. Aug 26, 2026 A Single-Dose Study of MT-201 and Concomitant Infliximab in Healthy Participants Infliximab Phase 1 Recruiting Mirador Therapeutics, Inc. Aug 20, 2026 An Interventional Study of Upadacitinib Extended-Release Tablets in Patients With Refractory Uveitis Adalimumab Phase 4 Active, not recruiting Tianjin Medical University Aug 19, 2026 The Efficacy of Lactobacillous Probiotic and Trace Elements in the Management of Ulcerative Colitis Patients the Patients Will be Recruited From Outpatient Clinic of Inflammatory Bowel Disease (IBD) of the National Hepatology and Tropical Medicine Research Institute NHTMRI, Cairo, Egypt Infliximab Phase 4 Recruiting National Hepatology & Tropical Medicine Research Institute Aug 11, 2026 The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer Adalimumab Phase 2 Not yet recruiting Suzhou Suncadia Biopharmaceuticals Co., Ltd. Jul 15, 2026 Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease Infliximab — Recruiting Shanghai 10th People's Hospital Jul 10, 2026 Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo Golimumab Phase 2 Not yet recruiting National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Jul 6, 2026 Infliximab for Immune Checkpoint Inhibitor Associated AKI Infliximab Phase 4 Recruiting Massachusetts General Hospital Jul 6, 2026 Safety and Efficacy of Topical Infliximab in Autoimmune Dry Eye Disease Infliximab Phase 2 Not yet recruiting Instituto de Oftalmología Fundación Conde de Valenciana Jun 26, 2026 Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma Infliximab Phase 2 Recruiting Naresh Bumma Jun 18, 2026 Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel Disease Certolizumab pegol, Golimumab — Recruiting Shmuel Kivity, MD Jun 12, 2026 Ex Vivo Perfusion of Gene-Edited Porcine Livers in Patients With Severe Hepatic Failure Etanercept Early phase 1 Active, not recruiting Xijing Hospital Apr 9, 2026 Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt Golimumab — Not yet recruiting Assiut University Mar 27, 2026 Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission Certolizumab pegol Not applicable Recruiting Marmara University Mar 25, 2026 Methotrexate Alone vs Methotrexate + Etanercept for Minimal/Low Disease Activity in Juvenile Idiopathic Arthritis Etanercept Phase 3 Enrolling by invitation University of Child Health Sciences and Children's Hospital, Lahore Feb 4, 2026 Utilization of a Microdevice for Psoriasis and Atopic Dermatitis Certolizumab pegol, Etanercept Phase 4 Not yet recruiting University of California, San Francisco Jan 20, 2026 Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD Etanercept Not applicable Recruiting First Affiliated Hospital of Zhejiang University Sep 22, 2025 A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers Certolizumab pegol, Etanercept, Golimumab Phase 4 Recruiting Taichung Veterans General Hospital Sep 2, 2025 Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Certolizumab pegol, Etanercept, Golimumab Phase 2 Recruiting NYU Langone Health Aug 24, 2025 SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) Certolizumab pegol — Recruiting Leiden University Medical Center Jun 15, 2025 Effect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis Etanercept Phase 4 Recruiting Nanfang Hospital, Southern Medical University Nov 27, 2024 A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants Golimumab — Active, not recruiting Bristol-Myers Squibb Nov 13, 2023 Ibd CAncer and seRious Infections in France (I-CARE 2) Golimumab — Recruiting Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives Oct 18, 2023 Certolizumab in Recurrent Implantation Failure (RIF) Certolizumab pegol Phase 3 Recruiting Assistance Publique - Hôpitaux de Paris Jul 5, 2023 Stand UP to Rheumatoid Arthritis (SUPRA) Certolizumab pegol Not applicable Recruiting Marie Hudson, MD Mar 31, 2022
Show all 31Diseases most associated with it Open Targets association score, 0 to 1; all associations
Crohn disease 0.62
Psoriasis vulgaris 0.61
Arthritic joint disease 0.57
Immune system disorder 0.56 Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1825 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-18. Gene name, function (UniProt P01375 , CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets